Pharmacoeconomic Guidelines: The Netherlands
Country/Region: The Netherlands
PE Guidelines
Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)
PDF in Dutch
PE Guidelines Source:
National Health Care Institute (ZIN)
http://www.zorginstituutnederland.nl
http://www.zorginstituutnederland.nl
Additional Information:
Costing Manual
PDF in Dutch
Manual on Quality of Life Measurements
PDF in Dutch
Uncertainty and Value of Information
PDF in English
Information current as of Monday, July 25, 2022
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | PE Guidelines |
| Title and year of the document | Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016) |
| Affiliation of authors | National Health Care Institute |
| Purpose of the document | Providing guidance for conduct of EE studies for reimbursement issues in order to improve their quality, credibility and comparability |
| Standard reporting format included | Yes |
| Disclosure | Yes |
| Target audience of funding/ author's interests | Who conduct economic evaluations or evaluate the economic evaluations studies (decision makers) |
| Perspective | Societal perspective. Report unrelated medical costs in life years gained seperately. |
| Indication | Approved indication; although sometimes off-label use is considered for comparator |
| Target population | Be clearly specify |
| Subgroup analysis | Yes |
| Choice of comparator | Standard of care or usual care in the Netherlands |
| Time horizon | Life time |
| Assumptions required | Yes |
| Preferred analytical technique | CUA |
| Costs to be included | Societal perspective. Report unrelated medical costs in life years seperately. |
| Source of costs | Reference prices list should be used |
| Modeling | Yes, requires details |
| Systematic review of evidences | Yes, encourage meta-analysis |
| Preference for effectiveness over efficacy | Yes, modelling on trial data and other sources is required |
| Preferred outcome measure | QALY and optional other measures of effectiveness like life years gained (LYG) |
| Preferred method to derive utility | EQ-5D-5L using Dutch value set |
| Equity issues stated | Yes |
| Discounting costs | 4% |
| Discounting outcomes | 1.5% |
| Sensitivity analysis-parameters and range | All key uncertain parameters, within a defined area and best/worst case scenario |
| Sensitivity analysis-methods | One-way, multi-way or scenario and probabilistic analysis |
| Presenting results | Must be clear. Total costs and effects, incremental costs and effects. Results sensitivity analysis in tables and appropriate figures |
| Incremental analysis | Yes |
| Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
| Portability of results (Generalizability) | Study must refer to national context; utilities preferable calculated using Dutch value sets |
| Financial impact analysis | Yes |
| Mandatory or recommended or voluntary | Mandatory |
Acknowledgement: